The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.

Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at treating neurological diseases. Astellas will ...

Two fundamental aspects of AAV research are the accurate quantification of AAV capsid titters and the detection of pre-existing antibodies against AAV. These measurements are essential for ensuring ...

The capsid license is pursuant to the agreement ... While naturally occurring AAV capsids lack precise targeting to deliver medicine to the right cells, are difficult to manufacture, and have ...

AAV is crucial for gene therapy, but accurate measurement of impurities like full-to-total capsid ratios is essential. AUC, a gold standard for AAV characterization, showed good repeatability but ...

Below is our list of the 31 largest contracts in MLB history by average annual value (AAV). Please note that if a player was already under contract and signed an extension, only the new money counts.